Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the benefits of MRD and compares it to some alternative methods of screening. This interview took place at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias.
How has MRD changed our ability to diagnose leukemia?
